Three conferences in two weeks. Right after the big cancer conference, is a big gene therapy conference, then the investors conference. Certainly likely to be a big couple weeks for cancer research and gene therapy.
academicpress.com
The Third Annual Meeting of the American Society of Gene Therapy
May 31 - June 4, 2000 Denver, Colorado
One should remember that these abstracts would probably have been written about 6 months ago. They may present more recent results at the meeting itself. Sounds like Sherwin may have a few things to talk about at the Investors meeting the following week.
academicpress.com
academicpress.com
academicpress.com
academicpress.com
academicpress.com
academicpress.com
academicpress.com
academicpress.com
academicpress.com
academicpress.com
academicpress.com
academicpress.com
IMPORTANT ADVANCES IN CANCER RESEARCH TO BE PRESENTED AT THE ASCO 2000 ANNUAL MEETING
More than 20,000 cancer professionals from around the world will gather at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO) at the
Ernest N. Morial Convention Center in New Orleans from May 20-23, 2000.
Beginning Saturday, May 20th, ASCO will hold seven media briefings featuring significant research being presented at the Annual Meeting, and reviewing important
areas of concern in the field of cancer care. All research is embargoed until the date and time of scientific presentation.
asco.org
Two weeks later is an investors conference
marketwatch.newsalert.com.
On Saturday June 3, Informed Investors will host its Fifth Beltway Biotechnology Stocks Forum highlighting genomics.
The keynote speaker is analyst Akhtar Samad, M.D., Ph.D., of Oscar Gruss & Co. Companies slated to present are Cell
Genesys, CuraGen, Gene Logic, Genome Therapeutics, Genzyme Molecular Oncology, Human Genome Sciences, ISIS
Pharmacueticals, Lynx Therapeutics, Sequenom, Targeted Genetics, Trega Biosciences, Vical and Vysis, Inc. Senior
management of the companies will give insights into strategic plans and prospects. |
